Combinations of Avibactam and Carbapenems Exhibit Enhanced Potencies Against Drug-Resistant Mycobacterium Abscessus
- 16 February 2017
- journal article
- Published by Taylor & Francis in Future Microbiology
- Vol. 12 (6) , 473-480
Abstract
Aim: The objective of this study was to assess if avibactam, a new β-lactamase inhibitor, can restore the potency of carbapenems, a sub-class of β-lactams, against Mycobacterium abscessus clinical isolates. Materials & methods: 28 M. abscessus clinical isolates that are resistant to multiple drugs currently used to treat its infection were included. MIC of carbapenems alone and in combination with avibactam against these strains were determined. Results: Tebipenem, an oral carbapenem, and ertapenem and panipenem exhibited the greatest shift in MIC when supplemented with avibactam. Conclusion: Avibactam restores MICs of tebipenem, ertapenem and panipenem against M. abscessus to therapeutically achievable concentrations and raises the possibility of usefulness of these carbapenems to treat drug-resistant M. abscessus infections.Keywords
This publication has 25 references indexed in Scilit:
- Inactivation of Mycobacterium tuberculosis l , d -Transpeptidase Ldt Mt1 by Carbapenems and CephalosporinsAntimicrobial Agents and Chemotherapy, 2012
- Antimicrobial Susceptibility Testing, Drug Resistance Mechanisms, and Therapy of Infections with Nontuberculous MycobacteriaClinical Microbiology Reviews, 2012
- Mycobacterium abscessus: a new antibiotic nightmareJournal of Antimicrobial Chemotherapy, 2012
- The Peptidoglycan of Mycobacterium abscessus Is Predominantly Cross-Linked by l , d -TranspeptidasesJournal of Bacteriology, 2011
- Nontuberculous Mycobacterial Lung Disease Prevalence at Four Integrated Health Care Delivery SystemsAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Pulmonary Nontuberculous Mycobacterial Disease Prevalence and Clinical Features: An Emerging Public Health DiseaseAmerican Journal of Respiratory and Critical Care Medicine, 2010
- Molecular Epidemiology ofMycobacterium abscessus, with Focus on Cystic FibrosisJournal of Clinical Microbiology, 2007
- Pharmacokinetics and pharmacodynamics of ertapenem: an overview for cliniciansJournal of Antimicrobial Chemotherapy, 2004
- Nontuberculous Mycobacteria: I: Multicenter Prevalence Study in Cystic FibrosisAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Panipenem/BetamipronDrugs, 2003